Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.

Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.

Despite the use of highly active antiretroviral therapies (HAART), a majority of Human Immunodeficiency Virus Type 1 (HIV) infected individuals continually develop HIV - Associated Neurocognitive Disorders (HAND), indicating that host inflammatory mediators, in addition to viral proteins, may be con...

Full description

Bibliographic Details
Main Authors:	Donna C Davidson, Giovanni Schifitto, Sanjay B Maggirwar
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3610700?pdf=render

Similar Items

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
by: Pelemans, H, et al.
Published: (1998)

Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors.
by: Auwerx, J, et al.
Published: (2004)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
by: Esnouf, R, et al.
Published: (1995)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
by: Murugesan Vanangamudi, et al.
Published: (2023-09-01)

Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)
by: Cui Deng, et al.
Published: (2022-12-01)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
by: Smeulders Liesbeth, et al.
Published: (2010-10-01)

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
by: Nicolas Tardiota, et al.
Published: (2024-01-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
by: Lívia da Rocha Fernandes, et al.
Published: (2023-11-01)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
by: Anna Stachowicz-Kuśnierz, et al.
Published: (2023-08-01)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility
by: Li-Min Zhao, et al.
Published: (2023-12-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
by: Chan, J, et al.
Published: (2001)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
by: Ren, J, et al.
Published: (2008)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition.
by: R Brad Jones, et al.
Published: (2008-01-01)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
by: Tanaka, H, et al.
Published: (1999)

STRUCTURAL STUDIES ON HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE
by: Stammers, D, et al.
Published: (1990)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
by: Milton, J, et al.
Published: (1998)

Exploring QSAR of non-nucleoside reverse transcriptase inhibitors by artificial neural networks: HEPT derivatives
by: Mohamed Zahouily, et al.
Published: (2007-09-01)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
by: Anthi Petrou, et al.
Published: (2019-10-01)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
by: Richa Dwivedi, et al.
Published: (2022-07-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
by: Freeman, G, et al.
Published: (2004)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
by: Hopkins, A, et al.
Published: (2004)

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Da Feng, et al.
Published: (2022-11-01)

Modeling of cytotoxicity on some non- nucleoside reverse transcriptase inhibitors of HIV-1: role of physicochemical parameters
by: B.K. Tiwari, et al.
Published: (2006-02-01)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium degeneration
by: Siddharth Narendran, et al.
Published: (2021-04-01)

Myocarditis in CD8-depleted SIV-infected rhesus macaques after short-term dual therapy with nucleoside and nucleotide reverse transcriptase inhibitors.
by: Lakshmanan Annamalai, et al.
Published: (2010-12-01)

Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting
by: Watcharananan Siriorn, et al.
Published: (2007-11-01)

The Lysine 65 Residue in HIV-1 Reverse Transcriptase Function and in Nucleoside Analog Drug Resistance
by: Scott J. Garforth, et al.
Published: (2014-10-01)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
by: Ren, J, et al.
Published: (2000)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
by: Ren, J, et al.
Published: (2002)